Cardiovascular Outcomes Trials

Cardiovascular Outcomes Trials

To search publications using the available search words, please click here:

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE‐IT Investigators. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI. J Am Heart Assoc. 2022; epub ahead of print.

https://www.ahajournals.org/doi/epub/10.1161/JAHA.121.022937

https://pubmed.ncbi.nlm.nih.gov/35261279/

Singh N, Bhatt DL, Miller M, Steg G, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Mason RP, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. J Am Coll Cardiol. 2022;79:220-222.

https://www.jacc.org/doi/10.1016/j.jacc.2021.11.005

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT REVASC. Circulation. 2021;143:33-44.

https://pubmed.ncbi.nlm.nih.gov/33148016/

Verma S, Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif J-C, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG. Circulation. 2021;144:1845-1855.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056290

https://pubmed.ncbi.nlm.nih.gov/34710343/

Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Budoff M, Mason RP, Tardif JC, Boden WE, Ballantyne CM; REDUCE-IT Investigators. Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation. 2021;144:1750-1759.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055560

https://pubmed.ncbi.nlm.nih.gov/34706555/

Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020;41(24):2304–2312.

https://doi.org/10.1093/eurheartj/ehz778

Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg G, Ketchum SB, Doyle RT Jr., Juliano RA, Jiao L, Granowitz C, Tardif J-C, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. REDUCE-IT USA: results from the 3,146 patients randomized in the United States. Circulation. 2019; epub ahead of print.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044440